4 research outputs found
sj-docx-1-tej-10.1177_20417314231201071 – Supplemental material for Advancements in cell-based therapies for the treatment of pressure injuries: A systematic review of interventional studies
No full textSupplemental material, sj-docx-1-tej-10.1177_20417314231201071 for Advancements in cell-based therapies for the treatment of pressure injuries: A systematic review of interventional studies by Alianda Camesi, Reto Wettstein, Ezra Valido, Nicole Nyfeler, Stevan Stojic, Marija Glisic, Jivko Stoyanov and Alessandro Bertolo in Journal of Tissue Engineering</p
sj-docx-2-tej-10.1177_20417314231201071 – Supplemental material for Advancements in cell-based therapies for the treatment of pressure injuries: A systematic review of interventional studies
No full textSupplemental material, sj-docx-2-tej-10.1177_20417314231201071 for Advancements in cell-based therapies for the treatment of pressure injuries: A systematic review of interventional studies by Alianda Camesi, Reto Wettstein, Ezra Valido, Nicole Nyfeler, Stevan Stojic, Marija Glisic, Jivko Stoyanov and Alessandro Bertolo in Journal of Tissue Engineering</p
Advancements in cell-based therapies for the treatment of pressure injuries: A systematic review of interventional studies
No full textThe high recurrence and complications associated with severe pressure injuries (PI) necessitate the exploration of advanced treatments, such as cell-based therapies, to facilitate wound healing. Such techniques harness the ability of different cell types to promote angiogenesis, re-epithelialization of the skin, and tissue regeneration. This systematic review explores the efficacy of cell-based therapies and tissue engineering in treating deep PI. We searched for interventional studies using cells in the treatment of PI in adults in four online libraries (PubMed, Embase, Ovid Medline, and Cochrane; latest search 10th June 2023). We found one randomized clinical trial (RCT), two non-RCT, and three pre-post studies, comprising 481 study participants with PI (253 intervention/228 controls). The risk of bias was categorized as moderate due to minimal bias in outcome measurements, or high owing to unclear patient randomization methods, as assessed by the ROBINS-I, NIH, and RoB-2 tools. Four cell types were identified in the context of cell-based therapies of PI: bone marrow mononuclear stem cells (BM-MNCs, n = 2); hematopoietic derived stem cells (HSC, n = 1); macrophages and activated macrophage suspensions (AMS, n = 2); and cryopreserved placental membrane containing viable cells (vCPM, n = 1). Wound healing outcomes were observed in patients undergoing cell-based therapies, including complete wound closure (AMS, vCPM; n = 142), faster healing rate (BM-MNCs, AMS; n = 146), improved granulation tissue formation (HSC, n = 3) and shorter hospitalization time (BM-MNCs; n = 108) compared to standard of care, with no adverse reactions. PI healing rate decreased only in one study with BM-MNC therapy, compared to control (n = 86). Based on the available data, though with limited evidence, it seems that macrophage deployment showed the most favorable outcomes. The results indicate that cell-based therapies offer a potential avenue for enhancing wound healing and tissue repair in PI; however, more extensive research is needed in this domain
